ADUS vs UNH: Which Is the Better Buy in 2026?
Last updated September 2026
Short answer
UNH is the larger of the two ($355.72B market cap): the incumbent the market prices for continued execution (17.66x forward earnings, beta 0.63). ADUS is the smaller challenger ($2.14B), cheaper on forward earnings (15.23x): more room to run, but more to prove. The real question is which set of drivers you believe, and whether owning one (or both) leaves you over-concentrated.
ADUS vs UNH: the tie-breaker metrics
Same yardstick, side by side (as of September 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.
| Metric | ADUS | UNH | What it tells you |
|---|---|---|---|
| Market cap | $2.14B | $355.72B | Size. The larger name is the incumbent; the smaller has more room to grow and more to prove. |
| Forward P/E | 15.23 | 17.66 | Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up. |
| Trailing P/E | 20.06 | 25.45 | Valuation on the last 12 months. A big drop from trailing to forward means the market expects earnings to jump, so more growth is already in the price. |
| Beta | 0.87 | 0.63 | Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through. |
| Price vs 52-week range | 73% of range | 68% of range | Where today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why. |
| Price / book | 1.83 | 3.64 | How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price. |
Reading it: ADUS is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.
Before you buy: how ADUS and UNH affect your concentration
The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. ADUS and UNH share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.
This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined ADUS and UNH exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.
What does Addus HomeCare Corporation (ADUS) do?
Addus HomeCare Corporation provides in-home care to elderly, chronically ill, and disabled people through three segments: personal care (help with bathing, dressing, meals, and daily activities), hospice (end-of-life care), and home health (skilled nursing and therapy). Personal care is by far the largest piece at roughly 77% of revenue and is funded predominantly by state Medicaid programs, while hospice and home health are largely Medicare-funded. The company operates across many states with heavy concentration in markets like Illinois, New Mexico, and Texas, and has grown for years through a steady stream of acquisitions, most recently a large personal care deal that lifted 2025 revenue sharply.
What does UnitedHealth Group (UNH) do?
UnitedHealth Group is the largest US health insurer and one of the largest healthcare companies in the world. It runs through two main engines. UnitedHealthcare is the insurance arm, providing employer, individual, Medicare Advantage, and Medicaid health plans to tens of millions of members. Optum is the faster-growing health-services arm: Optum Health (physician groups and care delivery, including value-based care), Optum Insight (healthcare data, analytics, and technology), and Optum Rx (one of the largest pharmacy benefit managers in the country). The combination lets UnitedHealth manage both the financing and the delivery of care, capturing margin across the system and using vast claims data to manage costs. Headquartered in Minnetonka, Minnesota, UnitedHealth is a Dow component and one of the largest companies in the S&P 500 by revenue. Its scale, vertical integration, and Medicare Advantage leadership define its competitive position.
ADUS vs UNH: how do they differ?
Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.
- ADUS drivers: Aging demographics and shift to home; Personal care volume and rate growth.
- UNH drivers: Optum growth engine; Medicare Advantage scale.
Which fits which kind of investor
A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: The largest risk is reimbursement concentration: personal care depends heavily on state Medicaid budgets and hospice and home health on Medicare, so rate cuts, budget shortfalls, or eligibility changes in key states can pressure revenue and margins directly. For UNH, unitedHealth faces a difficult medical-cost environment: rising utilization (especially in Medicare Advantage) can spike the medical loss ratio and compress margins, as the company has experienced.
ADUS or UNH: which should you pick?
Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick ADUS if you believe its drivers more; UNH if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the ADUS and UNH guides.
ADUS vs UNH: the full fundamentals
ADUS. Addus trades at a low-20s trailing earnings multiple, reflecting a steady, profitable services operator rather than a high-growth name. First quarter 2026 revenue of roughly $363.6 million missed some estimates while adjusted EPS beat, and net income rose about 18% year over year. The 2025 revenue jump was driven mostly by a large personal care acquisition, so underlying organic growth runs closer to mid-single digits.
UNH. UnitedHealth's revenue is enormous but its insurance margins are thin by design, so earnings hinge on the medical loss ratio and Optum's higher-margin growth. The valuation reflects scale and integration but has been pressured by cost inflation, regulatory uncertainty, and reputational headwinds. The market weighs Optum's durable growth against insurance-cycle and political risk.
Headline figures (approximate, July 2026): ADUS shows revenue (ttm) ~$1.44B, fy2025 revenue ~$1.42B (up ~23%), q1 2026 revenue ~$363.6M (up ~7.7%), q1 2026 adjusted eps ~$1.62 (up ~14%); UNH shows revenue (ttm) ~$400 billion, operating margin ~6-8%, net income (ttm) ~$15-22 billion (sensitive to medical costs), medical loss ratio ~85-89%.
The bottom line: ADUS vs UNH
ADUS and UNH are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined ADUS and UNH exposure against your real portfolio. It is not an investment adviser.
Wondering how ADUS or UNH fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Investing in Addus HomeCare Corporation with AI
Connect the broker you already use and ask Walnut's AI how ADUS fits what you actually hold: whether you own it already through a fund, what it would do to your concentration, and how it has tracked the S&P 500. Read-only by default, and you approve anything before it reaches your broker.
FAQ
What is the difference between ADUS and UNH?
+
Addus HomeCare Corporation provides in-home care to elderly, chronically ill, and disabled people through three segments: personal care (help with bathing, dressing, meals, and daily activities), hospice (end-of-life care), and home health (skilled nursing and therapy). UnitedHealth Group is the largest US health insurer and one of the largest healthcare companies in the world. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.
Is ADUS or UNH the better stock?
+
Neither is universally better. UNH is the larger incumbent; ADUS is the smaller challenger and looks cheaper on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.
Which is cheaper, ADUS or UNH?
+
On forward P/E (as of September 2026), ADUS trades at 15.23x and UNH at 17.66x, so ADUS is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.
Should you own both ADUS and UNH?
+
Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.
What are the risks of ADUS vs UNH?
+
ADUS: The largest risk is reimbursement concentration: personal care depends heavily on state Medicaid budgets and hospice and home health on Medicare, so rate cuts, budget shortfalls, or eligibility changes in key states can pressure revenue and margins directly. Proposed Medicaid or Medicare funding changes at the federal level are a recurring overhang. The business is labor-intensive, so caregiver wage inflation, turnover, and staffing shortages can squeeze already thin margins. Integration risk and the use of debt for acquisitions add execution and balance-sheet sensitivity. Finally, regulatory and compliance exposure across many states and government payers means audits, documentation requirements, and policy shifts are an ongoing part of the model. UNH: UnitedHealth faces a difficult medical-cost environment: rising utilization (especially in Medicare Advantage) can spike the medical loss ratio and compress margins, as the company has experienced. Regulatory and political risk is significant, including Medicare Advantage rate changes, scrutiny of PBM practices, and proposals to limit insurer-provider integration. The company has faced antitrust attention, a major cyberattack on its Change Healthcare unit, and intense public criticism of the insurance industry. Reimbursement is set by government programs that can change with each cycle. Litigation, regulatory fines, and reputational risk are persistent. Its size makes it a target for legislation, and any sustained period of elevated medical costs directly pressures earnings.
Related comparisons
Browse all stock comparisons.
Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell ADUS or UNH; figures are approximate and dated (as of September 2026). Verify current data before investing.